Equities Analysts Issue Forecasts for ARTV FY2025 Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Investment analysts at Cantor Fitzgerald cut their FY2025 EPS estimates for Artiva Biotherapeutics in a research report issued on Tuesday, March 25th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings of ($2.91) per share for the year, down from their prior estimate of ($2.72). Cantor Fitzgerald has a “Overweight” rating and a $20.00 price objective on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Artiva Biotherapeutics in a research note on Wednesday. Wedbush restated an “outperform” rating and issued a $18.00 target price on shares of Artiva Biotherapeutics in a research note on Tuesday. Finally, Needham & Company LLC reiterated a “buy” rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a research note on Tuesday. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $20.40.

Artiva Biotherapeutics Stock Performance

Shares of ARTV stock opened at $3.54 on Thursday. The stock’s 50-day moving average price is $4.78 and its 200 day moving average price is $9.29. Artiva Biotherapeutics has a 52-week low of $3.37 and a 52-week high of $17.31.

Institutional Investors Weigh In On Artiva Biotherapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets acquired a new stake in Artiva Biotherapeutics in the 3rd quarter valued at $42,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Artiva Biotherapeutics in the fourth quarter valued at about $52,000. Wells Fargo & Company MN raised its holdings in shares of Artiva Biotherapeutics by 64.0% during the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock valued at $87,000 after buying an additional 3,361 shares during the period. MetLife Investment Management LLC acquired a new position in Artiva Biotherapeutics during the 3rd quarter worth approximately $135,000. Finally, JPMorgan Chase & Co. purchased a new position in Artiva Biotherapeutics in the 3rd quarter worth approximately $166,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.